A citation-based method for searching scientific literature

Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T Ritchlin. Lancet 2020
Times Cited: 108



Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
Times Cited: 137




List of shared articles



Times cited

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty,[...]. Arthritis Rheumatol 2022
9

A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
Alessandra Michelucci, Flavia Manzo Margiotta, Salvatore Panduri, Annalisa Tonini, Marco Romanelli, Riccardo Morganti, Agata Janowska, Valentina Dini. Dermatol Ther 2022
1

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman, Alexa P Kollmeier, Xie L Xu, May Shawi, Chetan S Karyekar, Christine Contré,[...]. Rheumatology (Oxford) 2022
0

Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis.
Christine P Lin, Joseph F Merola, Elizabeth B Wallace. Curr Opin Pharmacol 2022
0

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng,[...]. Arthritis Rheumatol 2021
18


A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
6

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique R Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu,[...]. RMD Open 2021
13

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
19

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, Alexander Egeberg, Jashin J Wu. Am J Clin Dermatol 2021
21

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
Proton Rahman, Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Philip J Mease, Alice B Gottlieb, Shelly Kafka, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu,[...]. J Rheumatol 2021
2

Newer Therapies in Psoriasis.
Justin W Marson, Margaret L Snyder, Mark G Lebwohl. Med Clin North Am 2021
7

Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.
Georg Schett, Iain B McInnes, Markus F Neurath. N Engl J Med 2021
47


Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106